Inclusion Criteria:  PK Part:  Male and female participants with Japanese nationality. A diagnosis of congenital protein C deficiency (homozygous or compound heterozygous). Asymptomatic participant. Oral anticoagulants allowed to be received.  Extension part:  Participants who participated in the PK part of this study (TAK-662-1501). Participant who are; a. Diagnosed with PF, CISN/WISN, and/or other acute thromboembolic episode for on-demand treatment only; b. Requiring treatment with TAK-662 for short-term prophylaxis for surgical procedures; c. Requiring treatment with TAK-662 for long-term prophylaxis.  Exclusion Criteria:  PK Part:  Current or recurrent disease that could affect the action, or disposition of the investigational product (IP), or clinical or laboratory assessments. A body weight less than 8 kg. Serious liver dysfunction, judged by the investigator. Any thrombosis within 2 weeks prior to administration of the IP. Other investigational product than TAK-662 received within 60 days prior to the administration of the IP. Current or relevant history of physical or psychiatric illness, or any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the IP or procedures. Current use of any medication (including over-the-counter, herbal, or homeopathic preparations) that could affect (improve or worsen) the condition being studied, or could affect the action or disposition of the IP, or clinical or laboratory assessment. Known or suspected intolerance or hypersensitivity to the IP, closely-related compounds, or any of the stated ingredients. Known history of alcohol or other substance abuse within the last year. Within 30 days prior to the first dose of IP, a participant has been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this sponsored study.  Extension Part:  1. New serious medical conditions which could affect participant's safety or treatment were observed during participation in the PK part of this study (TAK-662-1501).